Arbele is a locally grown pharmaceutical biotech with over 30 scientists and staff focused on immunotherapy of advanced gastrointestinal cancers with a high mortality rate (such as liver, stomach, pancreas, oesophagus, colon and lung). The company is founded by accomplished, well-recognized scientists and senior executives from the pharmaceutical industry and teamed up with experienced professionals in business, accounting, finance and legal.
Arbele’s vision is to early detect and defeat gastrointestinal (GI) cancers with immunotherapeutics with breakthrough innovation. We strive to provide the first-in-class and best-in-class GI cancer drugs and premium in-vitro diagnostics for early disease intervention. Our exclusive worldwide patent coverage of CDH17, a novel target specific to the GI tract, means that we will be one of the leaders in the GI cancer field in providing a better, safer and cheaper treatment option to patients based on our range of robust pipelines on therapeutics and diagnostics products.
For more information: http://www.arbelebio.com
Our founder Dr. John Luk discovered CDH17 to be a highly specific “clean target” biomarker in the GI tract. This biomarker is over-expressed in cancer cells and is clinically correlated to GI cancers progression. Our current pipeline includes bispecific antibody (ARB202), CDH17 immunodiagnostics and 5th generation AI-CAR-NK/T platform.
ARB202 is a first-in-class humanized bispecific antibody targeting CDH17 on tumour cells and CD3 on T cells, its first-in-human clinical trial is underway in Australia, and patient screening will take place in Hong Kong in Q3 2022. Further INDs are expected to be submitted to NMPA (China) and FDA (US) in 2023.